About PreOmics - The founder team of PreOmics started working on optimized LC-MS proteomic workflows at the Matthias Mann lab in 2010. After establishing an optimized and easier sample preparation process in 2014, Dr. Nils A. Kulak together with Dr. Garwin Pichler set forth to validate their technologies with external laboratories and researchers. With a lot of support of proteomics experts, engineers and industry designers, they made their first product ready-for-market. The PreOmics team won several awards for their business idea, were supported by various accelerator programs and established their company in the beginning of 2016. They are now located at the IZB in Martinsried just south of Munich.

Learn! PreOmics^® solutions are also suitable for your cancer researches

N-glycomic identification of novel soft tissue prognostic biomarkers for oral cancer

Oral cancer: By combining semi-automated tissue homogenization on BeatBox® with high-resolution CE-LIF-based glycoanalysis, scientist from University of Debrecen and University of Pannonia created an efficient and sensitive workflow to identify novel glycobiomarkers in oral malignant lesions.

Deeper plasma proteome coverage enables identification of novel biomarkers and classification of diseases

Lung cancer: With ENRICH-iST, the coverage of the plasma proteome was improved by 2-fold, and an additional 21 upregulated biomarkers were identified in the samples collected from the non-small cell lung cancer (NSCLC) patients’ plasma.

Deeper plasma proteome coverage enables identification of novel biomarkers and classification of diseases

Colorectal cancer: ENRICH-iST provides a reliable, in-depth analysis of plasma with a clear distinction between colorectal patients and healthy donors.

Learn! PreOmics® solutions are also suitable for your cancer researches

Learn! PreOmics^® solutions are also suitable for your cancer researches